Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Johnson & Johnson (NYSE:Jnj) one of 10 best dip shares for billionaires. JP Morgan Analyst Chris Schott, Chris Schott, which is a $ 185 price target, maintained a rating about Johnson & Johnson (NYSE: JNJ).
Schott acknowledged that the company’s main work, the company’s innovative medicine and a meditech portfolio is well placed for more than 5% continuous growth. However, he also noted some main problems that annoy the optimism. Schott stressed the erosion of the sale of the steles due to the biosimilar competition he believed.
A series of smiles with baby care products in the foreground.
Moreover, the ongoing talc trial is an important limit. And finally, it is projected to be more than a pharmaceutical portfolio, with a prominent reduction in medications such as steels. As a result of these problems, Schotta remains carefully optimistic about Johnson & Johnson (NYSE: JNJ).
When we accept the potential of JNJ as an investment, we believe that certain AI shares offers more at the bottom potential and lower risk. If you are looking for an extremely worthless AI Stock to take advantage of the Trump-ERA tariffs and onhoring trends, please see our free report The best short-term EU reserve.
Read the next: The best and worst dow stocks for the next 12 months and 10 non-stop shares that can double your money.
Disclosure: No.
